Extrastriatal dopamine D 2 receptor binding in Huntington's disease (477 views)
Hum Brain Mapp (ISSN: 1065-9471, 1097-0193electronic, 1065-9471linking), 2011 Oct; 32(10): 1626-1636.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 5.88, 5-year impact factor: 6.348
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-80052670073&partnerID=40&md5=ad019b5a970419a268d97593d2d648e7
Keywords: [ 11c]flb 457, D 2 Receptors, Dopamine, Huntington, S Disease, Dopamine 2 Receptor, Isoremoxipride, Isoremoxipride C 11, Radioligand, Unclassified Drug, Adult, Aged, Article, Binding Affinity, Brain Cortex, Brain Size, Clinical Article, Clinical Assessment, Cognition, Controlled Study, Corpus Striatum, Disease Severity, Female, Human, Huntington Chorea, Ligand Binding, Neuroimaging, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Priority Journal, Rating Scale, Receptor Binding, Subcortex, Task Performance, Thalamus, Unified Huntington Disease Rating Scale, Volumetry, Brain Mapping, Carbon Isotopes, Dopamine Antagonists, Middle Aged, Positron-Emission Tomography, Protein Binding, Pyrrolidines, Salicylamides, Severity Of Illness Index, Statistics As Topic, Young Adult, [11c] Flb 457,
Affiliations:
*** IBB - CNR ***
PET Centre, Stockholm Brain Institute, Karolinska Institutet, Stockholm, Sweden
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Karolinska University Hospital, Stockholm 171 76, Sweden
NeuroSearch Sweden AB, Arvid Wallgrens Backe 20, 413 46, Göteborg, Sweden
References:
Aalto, S., Bruck, A., Laine, M., Nagren, K., Rinne, J.O., Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: A positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457 (2005) J Neurosci, 25, pp. 2471-247
Anderson, K.E., Marder, K.S., An overview of psychiatric symptoms in Huntington's disease (2001) Curr Psychiatry Rep, 3, pp. 379-388
Andrews, T.C., Weeks, R.A., Turjanski, N., Gunn, R.N., Watkins, L.H., Sahakian, B., Hodges, J.R., Brooks, D.J., Huntington's disease progression. PET and clinical observations (1999) Brain, 122, pp. 2353-2363
Backman, L., Ginovart, N., Dixon, R.A., Wahlin, T.B., Wahlin, A., Halldin, C., Farde, L., Age-related cognitive deficits mediated by changes in the striatal dopamine system (2000) Am J Psychiatry, 157, pp. 635-637
Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M.C., Dufour, N., Elalouf, J.-M., Brouillet, E., Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II (2008) Hum Mol Genet, 17, pp. 1446-1456
Bergstrom, M., Boethius, J., Eriksson, L., Greitz, T., Ribbe, T., Wideń, L., Head fixation device for reproducible position alignment in transmission CT and positron emission tomography (1981) J Comput Assist Tomogr, 5, pp. 136-141
Bonelli, R.M., Wenning, G.K., Pharmacological management of Huntington's disease: An evidence-based review (2006) Curr Pharm, 12, pp. 2701-2720
Brandt, J., Folstein, S.E., Wong, D.F., Links, J., Dannals, R.F., McDonnell-Sill, A., Starkstein, S., Tune, L.E., D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates (1990) J Neuropsychiatry Clin Neurosci, 2, pp. 20-27
Christian, B.T., Lehrer, D.S., Shi, B., Narayanan, T.K., Strohmeyer, P.S., Buchsbaum, M.S., Mantil, J.C., Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task (2006) Neuroimage, 31, pp. 139-152
Clark, M., Cramer III, R., The probability of chance correlation using partial least squares (PLS) (1993) Quant Struct Act Relat, 12, pp. 137-145
Craufurd, D., Snowden, J., Neuropsychological and neuropsychiatric aspects of Huntington's disease (2002) Huntington's Disease, pp. 62-69. , Bates G, Harper P, Jones L, editors. New York: Oxford University Press
DiProspero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H., Tagle, D.A., Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements (2004) J Neurocytol, 33, pp. 517-533
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Trygg, J., Wikström, C., Wold, S., Multi- and megavariate data analysis. PLS (2006) Basic Principles and Applications, , In: Umeå: Umetrics AB
Farde, L., Hall, H., Pauli, S., Halldin, C., Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man (1995) Synapse, 20, pp. 200-208
Farde, L., Suhara, T., Nyberg, S., Karlsson, P., Nakashima, Y., Hietala, J., Halldin, C., A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients (1997) Psychopharmacology (Berl), 133, pp. 396-404
Farde, L., Pauli, S., Hall, H., Eriksson, L., Halldin, C., Hogberg, T., Nilsson, L., Stone-Elander, S., Stereoselective binding of 11C-raclopride in living human brain-A search for extrastriatal central D2-dopamine receptors by PET (1998) Psychopharmacology (Berl), 94, pp. 471-478
Feigin, A., Tang, C., Ma, Y., Mattis, P., Zgaljardic, D., Guttman, M., Paulsen, J.S., Eidelberg, D., Thalamic metabolism and symptom onset in preclinical Huntington's disease (2007) Brain, 130, pp. 2858-2867
Folstein, S., (1989) Huntington's Disease: A Disorder of Families, , Baltimore: Johns Hopkins University Press
Gilbert, A.R., Rosenberg, D.R., Harenski, K., Spencer, S., Sweeney, J.A., Keshavan, M.S., Thalamic volumes in patients with first-episode schizophrenia (2001) Am J Psychiatry, 158, pp. 618-624
Ginovart, N., Lundin, A., Farde, L., Halldin, C., Backman, L., Swahn, C.G., Pauli, S., Sedvall, G., PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease (1997) Brain, 120, pp. 503-514
Gutekunst, C., Norflus, F., Hersch, S., The neuropathology of Huntington's disease (2002) Huntington's Disease, pp. 251-275. , Bates G, Harper P, Jones L, editors. New York: Oxford University Press
Hall, H., Farde, L., Halldin, C., Hurd, Y.L., Pauli, S., Sedvall, G., Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride (1996) Synapse, 23, pp. 115-123
Unified Huntington's disease rating scale: Reliability and consistency (1996) Mov Disord, 11, pp. 136-142. , Huntington Study Group (): -
Jackson, J.E., (1991) A user's guide to principle components, p. 592. , John Wiley and Sons, New York
Kessler, R.M., Whetsell, W.O., Ansari, M.S., Votaw, J.R., de Paulis, T., Clanton, J.A., Schmidt, D.E., Manning, R.G., Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride (1993) Brain Res, 609, pp. 237-243
Lammertsma, A.A., Hume, S.P., Simplified reference tissue model for PET receptor studies (1996) Neuroimage, 4, pp. 153-158
Langer, O., Halldin, C., Dollé, F., Swahn, C.G., Olsson, H., Lundkvist, P., Karlsson, H., Farde, L., Carbon-11 epidepride: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors (1999) Nucl Med Biol, 26, pp. 509-518
Lawrence, A.D., Weeks, R.A., Brooks, D.J., Andrews, T.C., Watkins, L.H., Harding, A.E., Robbins, T.W., Sahakian, B.J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Maglione, V., Cannella, M., Martino, T., Blasi, A., Frati, L., Squitieri, F., The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea (2006) Neurosci Lett, 393, pp. 27-30
Meltzer, C.C., Leal, J.P., Mayberg, H.S., Wagner Jr, H.N., Frost, J.J., Correction of PET data for partial volume effects in human cerebral cortex by MR imaging (1990) J Comput Assist Tomogr, 14, pp. 561-570
Mintun, M.A., Raichle, M.E., Kilbourn, M.R., Wooten, G.F., Welch, M.J., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) Ann Neurol, 15, pp. 217-227
Modregger, J., DiProspero, N.A., Charles, V., Tagle, D.A., Plomann, M., PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains (2002) Hum Mol Genet, 11, pp. 2547-2558
Okauchi, T., Suhara, T., Maeda, J., Kawabe, K., Obayashi, S., Suzuki, K., Effect of endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET (2001) Synapse, 41, pp. 87-95
Olsson, H., Farde, L., Potentials and pitfalls using high affinity radioligands in PET and SPECT determinations on regional drug induced D2 receptor occupancy-A simulation study based on experimental data (2001) Neuroimage, 14, pp. 936-945
Pavese, N., Andrews, T.C., Brooks, D.J., Ho, A.K., Rosser, A.E., Barker, R.A., Robbins, T.W., Piccini, P., Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease, a PET study (2003) Brain, 126, pp. 1127-1135
Pavese, N., Politis, M., Tai, Y.F., Barker, R.A., Tabrizi, S.J., Mason, S.L., Brooks, D.J., Piccini, P., Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers (2010) Neurobiol Dis, 37, pp. 356-361
Politis, M., Pavese, N., Tai, Y.F., Tabrizi, S.J., Barker, R.A., Piccini, P., Hypothalamic involvement in Huntington's disease: An in vivo PET study (2008) Brain, 131, pp. 2860-2869
Reading, S.A.J., Dziorny, A.C., Peroutka, L.A., Schreiber, M., Gourley, L.M., Yallapragada, V., Rosenblatt, A., Ross, C.A., Functional brain changes in presymptomatic Huntington's disease (2004) Ann Neurol, 55, pp. 879-883
Reisine, T.D., Fields, J.Z., Stern, L.Z., Johnson, P.C., Bird, E.D., Yamamura, H.I., Alterations in dopaminergic receptors in Huntington's disease (1977) Life Sci, 21, pp. 1123-1128
Roland, P.E., Zilles, K., Brain atlases-A new research tool (1994) Trends Neurosci, 17, pp. 458-467
Rominger, A., Wagner, E., Mille, E., Boning, G., Esmaeilzadeh, M., Wangler, B., Gildehaus, F.J., Cumming, P., Endogenous competition against binding of [18F]DMFP and [18F]Fallypride to dopamine D2/3 receptors in brain of living mouse (2009) Synapse, 64, pp. 313-322
Rosas, H.D., Hevelone, N.D., Zaleta, A.K., Greve, D.N., Salat, D.H., Fischl, B., Regional cortical thinning in preclinical Huntington disease and its relationship to cognition (2005) Neurology, 65, pp. 745-747
Rosas, H.D., Salat, D.H., Lee, S.Y., Zaleta, A.K., Pappu, V., Fischl, B., Greve, D., Hersch, S.M., Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity (2008) Brain, 131, pp. 1057-1068
Strong, T.V., Tagle, D.A., Valdes, J.M., Elmer, L.W., Boehm, K., Swaroop, M., Kaatz, K.W., Albin, R.L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues (1993) Nat Genet, 5, pp. 259-265
Suhara, T., Sudo, Y., Okauchi, T., Maeda, J., Kawabe, K., Suzuki, K., Okubo, Y., Farde, L., Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET (1999) Int J Neuropsychopharmacol, 2, pp. 73-82
Squitieri, F., Gellera, C., Cannella, M., Mariotti, C., Cislaghi, G., Rubinsztein, D.C., Almqvist, E.W., Donato, S., Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course (2003) Brain, 126, pp. 946-955
Tang, T.S., Chen, X., Liu, J., Bezprozvanny, I., Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (2007) J Neurosci, 27, pp. 7899-7910
van Oostrom, J.C., Dekker, M., Willemsen, A.T., de Jong, B.M., Roos, R.A., Leenders, K.L., Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease (2009) Eur J Neurol, 16, pp. 226-231
van Vugt, J.P., van Hilten, B.J., Roos, R.A., Hypokinesia in Huntington's disease (1996) Mov Disord, 11, pp. 384-388
Varrone, A., Sjoholm, N., Eriksson, L., Gulya's, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1639-1650
Volkow, N.D., Gur, R.C., Wang, G.J., Fowler, J.S., Moberg, P.J., Ding, Y.S., Hitzemann, R., Logan, J., Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals (1998) Am J Psychiatry, 155, pp. 344-349
Walker, F.O., Huntington's disease (2007) Semin Neurol, 27, pp. 143-150
Weeks, R.A., Piccini, P., Harding, A.E., Brooks, D.J., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (1996) Ann Neurol, 40, pp. 49-54
Wold, S., Cross-validatory estimation of the number of components in factor and principal component models (1978) Tecnometrics, 20, pp. 397-405
Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B., Ehrenkaufer, R., Hichwa, R., PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline (1986) Ann Neurol, 20, pp. 296-230
Anderson, K. E., Marder, K. S., An overview of psychiatric symptoms in Huntington's disease (2001) Curr Psychiatry Rep, 3, pp. 379-388
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H., Sahakian, B., Hodges, J. R., Brooks, D. J., Huntington's disease progression. PET and clinical observations (1999) Brain, 122, pp. 2353-2363
Bonelli, R. M., Wenning, G. K., Pharmacological management of Huntington's disease: An evidence-based review (2006) Curr Pharm, 12, pp. 2701-2720
Christian, B. T., Lehrer, D. S., Shi, B., Narayanan, T. K., Strohmeyer, P. S., Buchsbaum, M. S., Mantil, J. C., Measuring dopamine neuromodulation in the thalamus: Using [F-18] fallypride PET to study dopamine release during a spatial attention task (2006) Neuroimage, 31, pp. 139-152
DiProspero, N. A., Chen, E. Y., Charles, V., Plomann, M., Kordower, J. H., Tagle, D. A., Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements (2004) J Neurocytol, 33, pp. 517-533
Gilbert, A. R., Rosenberg, D. R., Harenski, K., Spencer, S., Sweeney, J. A., Keshavan, M. S., Thalamic volumes in patients with first-episode schizophrenia (2001) Am J Psychiatry, 158, pp. 618-624
Jackson, J. E., (1991) A user's guide to principle components, p. 592. , John Wiley and Sons, New York
Kessler, R. M., Whetsell, W. O., Ansari, M. S., Votaw, J. R., de Paulis, T., Clanton, J. A., Schmidt, D. E., Manning, R. G., Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I] epidepride (1993) Brain Res, 609, pp. 237-243
Lammertsma, A. A., Hume, S. P., Simplified reference tissue model for PET receptor studies (1996) Neuroimage, 4, pp. 153-158
Lawrence, A. D., Weeks, R. A., Brooks, D. J., Andrews, T. C., Watkins, L. H., Harding, A. E., Robbins, T. W., Sahakian, B. J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Meltzer, C. C., Leal, J. P., Mayberg, H. S., Wagner Jr, H. N., Frost, J. J., Correction of PET data for partial volume effects in human cerebral cortex by MR imaging (1990) J Comput Assist Tomogr, 14, pp. 561-570
Mintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., Welch, M. J., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) Ann Neurol, 15, pp. 217-227
Reading, S. A. J., Dziorny, A. C., Peroutka, L. A., Schreiber, M., Gourley, L. M., Yallapragada, V., Rosenblatt, A., Ross, C. A., Functional brain changes in presymptomatic Huntington's disease (2004) Ann Neurol, 55, pp. 879-883
Reisine, T. D., Fields, J. Z., Stern, L. Z., Johnson, P. C., Bird, E. D., Yamamura, H. I., Alterations in dopaminergic receptors in Huntington's disease (1977) Life Sci, 21, pp. 1123-1128
Roland, P. E., Zilles, K., Brain atlases-A new research tool (1994) Trends Neurosci, 17, pp. 458-467
Rosas, H. D., Hevelone, N. D., Zaleta, A. K., Greve, D. N., Salat, D. H., Fischl, B., Regional cortical thinning in preclinical Huntington disease and its relationship to cognition (2005) Neurology, 65, pp. 745-747
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., Greve, D., Hersch, S. M., Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity (2008) Brain, 131, pp. 1057-1068
Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., Kaatz, K. W., Albin, R. L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues (1993) Nat Genet, 5, pp. 259-265
Tang, T. S., Chen, X., Liu, J., Bezprozvanny, I., Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (2007) J Neurosci, 27, pp. 7899-7910
van Oostrom, J. C., Dekker, M., Willemsen, A. T., de Jong, B. M., Roos, R. A., Leenders, K. L., Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease (2009) Eur J Neurol, 16, pp. 226-231
van Vugt, J. P., van Hilten, B. J., Roos, R. A., Hypokinesia in Huntington's disease (1996) Mov Disord, 11, pp. 384-388
Volkow, N. D., Gur, R. C., Wang, G. J., Fowler, J. S., Moberg, P. J., Ding, Y. S., Hitzemann, R., Logan, J., Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals (1998) Am J Psychiatry, 155, pp. 344-349
Walker, F. O., Huntington's disease (2007) Semin Neurol, 27, pp. 143-150
Weeks, R. A., Piccini, P., Harding, A. E., Brooks, D. J., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (1996) Ann Neurol, 40, pp. 49-54
Young, A. B., Penney, J. B., Starosta-Rubinstein, S., Markel, D. S., Berent, S., Giordani, B., Ehrenkaufer, R., Hichwa, R., PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline (1986) Ann Neurol, 20, pp. 296-230
Hum Brain Mapp (ISSN: 1065-9471, 1097-0193electronic, 1065-9471linking), 2011 Oct; 32(10): 1626-1636.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 5.88, 5-year impact factor: 6.348
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-80052670073&partnerID=40&md5=ad019b5a970419a268d97593d2d648e7
Keywords: [ 11c]flb 457, D 2 Receptors, Dopamine, Huntington, S Disease, Dopamine 2 Receptor, Isoremoxipride, Isoremoxipride C 11, Radioligand, Unclassified Drug, Adult, Aged, Article, Binding Affinity, Brain Cortex, Brain Size, Clinical Article, Clinical Assessment, Cognition, Controlled Study, Corpus Striatum, Disease Severity, Female, Human, Huntington Chorea, Ligand Binding, Neuroimaging, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Priority Journal, Rating Scale, Receptor Binding, Subcortex, Task Performance, Thalamus, Unified Huntington Disease Rating Scale, Volumetry, Brain Mapping, Carbon Isotopes, Dopamine Antagonists, Middle Aged, Positron-Emission Tomography, Protein Binding, Pyrrolidines, Salicylamides, Severity Of Illness Index, Statistics As Topic, Young Adult, [11c] Flb 457,
Affiliations:
*** IBB - CNR ***
PET Centre, Stockholm Brain Institute, Karolinska Institutet, Stockholm, Sweden
Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Karolinska University Hospital, Stockholm 171 76, Sweden
NeuroSearch Sweden AB, Arvid Wallgrens Backe 20, 413 46, Göteborg, Sweden
References:
Aalto, S., Bruck, A., Laine, M., Nagren, K., Rinne, J.O., Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: A positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457 (2005) J Neurosci, 25, pp. 2471-247
Anderson, K.E., Marder, K.S., An overview of psychiatric symptoms in Huntington's disease (2001) Curr Psychiatry Rep, 3, pp. 379-388
Andrews, T.C., Weeks, R.A., Turjanski, N., Gunn, R.N., Watkins, L.H., Sahakian, B., Hodges, J.R., Brooks, D.J., Huntington's disease progression. PET and clinical observations (1999) Brain, 122, pp. 2353-2363
Backman, L., Ginovart, N., Dixon, R.A., Wahlin, T.B., Wahlin, A., Halldin, C., Farde, L., Age-related cognitive deficits mediated by changes in the striatal dopamine system (2000) Am J Psychiatry, 157, pp. 635-637
Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M.C., Dufour, N., Elalouf, J.-M., Brouillet, E., Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II (2008) Hum Mol Genet, 17, pp. 1446-1456
Bergstrom, M., Boethius, J., Eriksson, L., Greitz, T., Ribbe, T., Wideń, L., Head fixation device for reproducible position alignment in transmission CT and positron emission tomography (1981) J Comput Assist Tomogr, 5, pp. 136-141
Bonelli, R.M., Wenning, G.K., Pharmacological management of Huntington's disease: An evidence-based review (2006) Curr Pharm, 12, pp. 2701-2720
Brandt, J., Folstein, S.E., Wong, D.F., Links, J., Dannals, R.F., McDonnell-Sill, A., Starkstein, S., Tune, L.E., D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates (1990) J Neuropsychiatry Clin Neurosci, 2, pp. 20-27
Christian, B.T., Lehrer, D.S., Shi, B., Narayanan, T.K., Strohmeyer, P.S., Buchsbaum, M.S., Mantil, J.C., Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task (2006) Neuroimage, 31, pp. 139-152
Clark, M., Cramer III, R., The probability of chance correlation using partial least squares (PLS) (1993) Quant Struct Act Relat, 12, pp. 137-145
Craufurd, D., Snowden, J., Neuropsychological and neuropsychiatric aspects of Huntington's disease (2002) Huntington's Disease, pp. 62-69. , Bates G, Harper P, Jones L, editors. New York: Oxford University Press
DiProspero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H., Tagle, D.A., Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements (2004) J Neurocytol, 33, pp. 517-533
Eriksson, L., Johansson, E., Kettaneh-Wold, N., Trygg, J., Wikström, C., Wold, S., Multi- and megavariate data analysis. PLS (2006) Basic Principles and Applications, , In: Umeå: Umetrics AB
Farde, L., Hall, H., Pauli, S., Halldin, C., Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man (1995) Synapse, 20, pp. 200-208
Farde, L., Suhara, T., Nyberg, S., Karlsson, P., Nakashima, Y., Hietala, J., Halldin, C., A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients (1997) Psychopharmacology (Berl), 133, pp. 396-404
Farde, L., Pauli, S., Hall, H., Eriksson, L., Halldin, C., Hogberg, T., Nilsson, L., Stone-Elander, S., Stereoselective binding of 11C-raclopride in living human brain-A search for extrastriatal central D2-dopamine receptors by PET (1998) Psychopharmacology (Berl), 94, pp. 471-478
Feigin, A., Tang, C., Ma, Y., Mattis, P., Zgaljardic, D., Guttman, M., Paulsen, J.S., Eidelberg, D., Thalamic metabolism and symptom onset in preclinical Huntington's disease (2007) Brain, 130, pp. 2858-2867
Folstein, S., (1989) Huntington's Disease: A Disorder of Families, , Baltimore: Johns Hopkins University Press
Gilbert, A.R., Rosenberg, D.R., Harenski, K., Spencer, S., Sweeney, J.A., Keshavan, M.S., Thalamic volumes in patients with first-episode schizophrenia (2001) Am J Psychiatry, 158, pp. 618-624
Ginovart, N., Lundin, A., Farde, L., Halldin, C., Backman, L., Swahn, C.G., Pauli, S., Sedvall, G., PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease (1997) Brain, 120, pp. 503-514
Gutekunst, C., Norflus, F., Hersch, S., The neuropathology of Huntington's disease (2002) Huntington's Disease, pp. 251-275. , Bates G, Harper P, Jones L, editors. New York: Oxford University Press
Hall, H., Farde, L., Halldin, C., Hurd, Y.L., Pauli, S., Sedvall, G., Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride (1996) Synapse, 23, pp. 115-123
Unified Huntington's disease rating scale: Reliability and consistency (1996) Mov Disord, 11, pp. 136-142. , Huntington Study Group (): -
Jackson, J.E., (1991) A user's guide to principle components, p. 592. , John Wiley and Sons, New York
Kessler, R.M., Whetsell, W.O., Ansari, M.S., Votaw, J.R., de Paulis, T., Clanton, J.A., Schmidt, D.E., Manning, R.G., Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride (1993) Brain Res, 609, pp. 237-243
Lammertsma, A.A., Hume, S.P., Simplified reference tissue model for PET receptor studies (1996) Neuroimage, 4, pp. 153-158
Langer, O., Halldin, C., Dollé, F., Swahn, C.G., Olsson, H., Lundkvist, P., Karlsson, H., Farde, L., Carbon-11 epidepride: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors (1999) Nucl Med Biol, 26, pp. 509-518
Lawrence, A.D., Weeks, R.A., Brooks, D.J., Andrews, T.C., Watkins, L.H., Harding, A.E., Robbins, T.W., Sahakian, B.J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Maglione, V., Cannella, M., Martino, T., Blasi, A., Frati, L., Squitieri, F., The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea (2006) Neurosci Lett, 393, pp. 27-30
Meltzer, C.C., Leal, J.P., Mayberg, H.S., Wagner Jr, H.N., Frost, J.J., Correction of PET data for partial volume effects in human cerebral cortex by MR imaging (1990) J Comput Assist Tomogr, 14, pp. 561-570
Mintun, M.A., Raichle, M.E., Kilbourn, M.R., Wooten, G.F., Welch, M.J., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) Ann Neurol, 15, pp. 217-227
Modregger, J., DiProspero, N.A., Charles, V., Tagle, D.A., Plomann, M., PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains (2002) Hum Mol Genet, 11, pp. 2547-2558
Okauchi, T., Suhara, T., Maeda, J., Kawabe, K., Obayashi, S., Suzuki, K., Effect of endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET (2001) Synapse, 41, pp. 87-95
Olsson, H., Farde, L., Potentials and pitfalls using high affinity radioligands in PET and SPECT determinations on regional drug induced D2 receptor occupancy-A simulation study based on experimental data (2001) Neuroimage, 14, pp. 936-945
Pavese, N., Andrews, T.C., Brooks, D.J., Ho, A.K., Rosser, A.E., Barker, R.A., Robbins, T.W., Piccini, P., Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease, a PET study (2003) Brain, 126, pp. 1127-1135
Pavese, N., Politis, M., Tai, Y.F., Barker, R.A., Tabrizi, S.J., Mason, S.L., Brooks, D.J., Piccini, P., Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers (2010) Neurobiol Dis, 37, pp. 356-361
Politis, M., Pavese, N., Tai, Y.F., Tabrizi, S.J., Barker, R.A., Piccini, P., Hypothalamic involvement in Huntington's disease: An in vivo PET study (2008) Brain, 131, pp. 2860-2869
Reading, S.A.J., Dziorny, A.C., Peroutka, L.A., Schreiber, M., Gourley, L.M., Yallapragada, V., Rosenblatt, A., Ross, C.A., Functional brain changes in presymptomatic Huntington's disease (2004) Ann Neurol, 55, pp. 879-883
Reisine, T.D., Fields, J.Z., Stern, L.Z., Johnson, P.C., Bird, E.D., Yamamura, H.I., Alterations in dopaminergic receptors in Huntington's disease (1977) Life Sci, 21, pp. 1123-1128
Roland, P.E., Zilles, K., Brain atlases-A new research tool (1994) Trends Neurosci, 17, pp. 458-467
Rominger, A., Wagner, E., Mille, E., Boning, G., Esmaeilzadeh, M., Wangler, B., Gildehaus, F.J., Cumming, P., Endogenous competition against binding of [18F]DMFP and [18F]Fallypride to dopamine D2/3 receptors in brain of living mouse (2009) Synapse, 64, pp. 313-322
Rosas, H.D., Hevelone, N.D., Zaleta, A.K., Greve, D.N., Salat, D.H., Fischl, B., Regional cortical thinning in preclinical Huntington disease and its relationship to cognition (2005) Neurology, 65, pp. 745-747
Rosas, H.D., Salat, D.H., Lee, S.Y., Zaleta, A.K., Pappu, V., Fischl, B., Greve, D., Hersch, S.M., Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity (2008) Brain, 131, pp. 1057-1068
Strong, T.V., Tagle, D.A., Valdes, J.M., Elmer, L.W., Boehm, K., Swaroop, M., Kaatz, K.W., Albin, R.L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues (1993) Nat Genet, 5, pp. 259-265
Suhara, T., Sudo, Y., Okauchi, T., Maeda, J., Kawabe, K., Suzuki, K., Okubo, Y., Farde, L., Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET (1999) Int J Neuropsychopharmacol, 2, pp. 73-82
Squitieri, F., Gellera, C., Cannella, M., Mariotti, C., Cislaghi, G., Rubinsztein, D.C., Almqvist, E.W., Donato, S., Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course (2003) Brain, 126, pp. 946-955
Tang, T.S., Chen, X., Liu, J., Bezprozvanny, I., Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (2007) J Neurosci, 27, pp. 7899-7910
van Oostrom, J.C., Dekker, M., Willemsen, A.T., de Jong, B.M., Roos, R.A., Leenders, K.L., Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease (2009) Eur J Neurol, 16, pp. 226-231
van Vugt, J.P., van Hilten, B.J., Roos, R.A., Hypokinesia in Huntington's disease (1996) Mov Disord, 11, pp. 384-388
Varrone, A., Sjoholm, N., Eriksson, L., Gulya's, B., Halldin, C., Farde, L., Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) Eur J Nucl Med Mol Imaging, 36, pp. 1639-1650
Volkow, N.D., Gur, R.C., Wang, G.J., Fowler, J.S., Moberg, P.J., Ding, Y.S., Hitzemann, R., Logan, J., Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals (1998) Am J Psychiatry, 155, pp. 344-349
Walker, F.O., Huntington's disease (2007) Semin Neurol, 27, pp. 143-150
Weeks, R.A., Piccini, P., Harding, A.E., Brooks, D.J., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (1996) Ann Neurol, 40, pp. 49-54
Wold, S., Cross-validatory estimation of the number of components in factor and principal component models (1978) Tecnometrics, 20, pp. 397-405
Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B., Ehrenkaufer, R., Hichwa, R., PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline (1986) Ann Neurol, 20, pp. 296-230
Anderson, K. E., Marder, K. S., An overview of psychiatric symptoms in Huntington's disease (2001) Curr Psychiatry Rep, 3, pp. 379-388
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H., Sahakian, B., Hodges, J. R., Brooks, D. J., Huntington's disease progression. PET and clinical observations (1999) Brain, 122, pp. 2353-2363
Bonelli, R. M., Wenning, G. K., Pharmacological management of Huntington's disease: An evidence-based review (2006) Curr Pharm, 12, pp. 2701-2720
Christian, B. T., Lehrer, D. S., Shi, B., Narayanan, T. K., Strohmeyer, P. S., Buchsbaum, M. S., Mantil, J. C., Measuring dopamine neuromodulation in the thalamus: Using [F-18] fallypride PET to study dopamine release during a spatial attention task (2006) Neuroimage, 31, pp. 139-152
DiProspero, N. A., Chen, E. Y., Charles, V., Plomann, M., Kordower, J. H., Tagle, D. A., Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements (2004) J Neurocytol, 33, pp. 517-533
Gilbert, A. R., Rosenberg, D. R., Harenski, K., Spencer, S., Sweeney, J. A., Keshavan, M. S., Thalamic volumes in patients with first-episode schizophrenia (2001) Am J Psychiatry, 158, pp. 618-624
Jackson, J. E., (1991) A user's guide to principle components, p. 592. , John Wiley and Sons, New York
Kessler, R. M., Whetsell, W. O., Ansari, M. S., Votaw, J. R., de Paulis, T., Clanton, J. A., Schmidt, D. E., Manning, R. G., Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I] epidepride (1993) Brain Res, 609, pp. 237-243
Lammertsma, A. A., Hume, S. P., Simplified reference tissue model for PET receptor studies (1996) Neuroimage, 4, pp. 153-158
Lawrence, A. D., Weeks, R. A., Brooks, D. J., Andrews, T. C., Watkins, L. H., Harding, A. E., Robbins, T. W., Sahakian, B. J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Meltzer, C. C., Leal, J. P., Mayberg, H. S., Wagner Jr, H. N., Frost, J. J., Correction of PET data for partial volume effects in human cerebral cortex by MR imaging (1990) J Comput Assist Tomogr, 14, pp. 561-570
Mintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., Welch, M. J., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography (1984) Ann Neurol, 15, pp. 217-227
Reading, S. A. J., Dziorny, A. C., Peroutka, L. A., Schreiber, M., Gourley, L. M., Yallapragada, V., Rosenblatt, A., Ross, C. A., Functional brain changes in presymptomatic Huntington's disease (2004) Ann Neurol, 55, pp. 879-883
Reisine, T. D., Fields, J. Z., Stern, L. Z., Johnson, P. C., Bird, E. D., Yamamura, H. I., Alterations in dopaminergic receptors in Huntington's disease (1977) Life Sci, 21, pp. 1123-1128
Roland, P. E., Zilles, K., Brain atlases-A new research tool (1994) Trends Neurosci, 17, pp. 458-467
Rosas, H. D., Hevelone, N. D., Zaleta, A. K., Greve, D. N., Salat, D. H., Fischl, B., Regional cortical thinning in preclinical Huntington disease and its relationship to cognition (2005) Neurology, 65, pp. 745-747
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., Greve, D., Hersch, S. M., Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity (2008) Brain, 131, pp. 1057-1068
Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., Kaatz, K. W., Albin, R. L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues (1993) Nat Genet, 5, pp. 259-265
Tang, T. S., Chen, X., Liu, J., Bezprozvanny, I., Dopaminergic signaling and striatal neurodegeneration in Huntington's disease (2007) J Neurosci, 27, pp. 7899-7910
van Oostrom, J. C., Dekker, M., Willemsen, A. T., de Jong, B. M., Roos, R. A., Leenders, K. L., Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease (2009) Eur J Neurol, 16, pp. 226-231
van Vugt, J. P., van Hilten, B. J., Roos, R. A., Hypokinesia in Huntington's disease (1996) Mov Disord, 11, pp. 384-388
Volkow, N. D., Gur, R. C., Wang, G. J., Fowler, J. S., Moberg, P. J., Ding, Y. S., Hitzemann, R., Logan, J., Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals (1998) Am J Psychiatry, 155, pp. 344-349
Walker, F. O., Huntington's disease (2007) Semin Neurol, 27, pp. 143-150
Weeks, R. A., Piccini, P., Harding, A. E., Brooks, D. J., Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease (1996) Ann Neurol, 40, pp. 49-54
Young, A. B., Penney, J. B., Starosta-Rubinstein, S., Markel, D. S., Berent, S., Giordani, B., Ehrenkaufer, R., Hichwa, R., PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline (1986) Ann Neurol, 20, pp. 296-230
Extrastriatal dopamine D 2 receptor binding in Huntington's disease
Huntington's disease (HD) is a neurodegenerative disorder, primarily affecting medium spiny neurones in the striatum. The density of striatal dopamine D 2 receptors is reduced in HD but there is little known about this biomarker in brain regions outside the striatum. The primary objective of this study was to compare extrastriatal dopamine D 2 receptor binding, in age-matched control subjects and patients with HD. All subjects were examined using a high-resolution positron emission tomography system and the high-affinity dopamine D 2 receptor radioligand [ 11C]FLB 457. A ROI based analysis was used with an atrophy correction method. Dopamine D 2 receptor binding potential was reduced in the striatum of patients with HD. Unlike the striatum, dopamine D 2 receptor binding in thalamic and cortical subregions was not significantly different from that in control subjects. A partial least square regression analysis which included binding potential values from all investigated cortical and subcortical regions revealed a significant model separating patients from controls, conclusively dependent on differences in striatal binding of the radioligand. Some clinical assessments correlated with striatal dopamine D 2 receptor binding, including severity of chorea and cognitive test performance. Hence, the present study demonstrates that dopamine D 2 receptors extrinsic to the striatum are well preserved in early to mid stage patients with HD. This observation may have implication for the development of therapy for HD. © 2010 Wiley-Liss, Inc.
Huntington's disease (HD) is a neurodegenerative disorder, primarily affecting medium spiny neurones in the striatum. The density of striatal dopamine D 2 receptors is reduced in HD but there is little known about this biomarker in brain regions outside the striatum. The primary objective of this study was to compare extrastriatal dopamine D 2 receptor binding, in age-matched control subjects and patients with HD. All subjects were examined using a high-resolution positron emission tomography system and the high-affinity dopamine D 2 receptor radioligand [ 11C]FLB 457. A ROI based analysis was used with an atrophy correction method. Dopamine D 2 receptor binding potential was reduced in the striatum of patients with HD. Unlike the striatum, dopamine D 2 receptor binding in thalamic and cortical subregions was not significantly different from that in control subjects. A partial least square regression analysis which included binding potential values from all investigated cortical and subcortical regions revealed a significant model separating patients from controls, conclusively dependent on differences in striatal binding of the radioligand. Some clinical assessments correlated with striatal dopamine D 2 receptor binding, including severity of chorea and cognitive test performance. Hence, the present study demonstrates that dopamine D 2 receptors extrinsic to the striatum are well preserved in early to mid stage patients with HD. This observation may have implication for the development of therapy for HD. © 2010 Wiley-Liss, Inc.
Extrastriatal dopamine D 2 receptor binding in Huntington's disease
| ▼ Characterization of neurotoxic and neuroprotective factors by using computational methodologies |
Extrastriatal dopamine D 2 receptor binding in Huntington's disease
Other filter: ([btitle,keywords] "[ 11c]flb 457" OR [b ...
Pepe G, Calce E, Verdoliva V, Saviano M, Maglione V, Di Pardo A, De Luca S
* Curcumin-Loaded Nanoparticles Based on Amphiphilic Hyaluronan-Conjugate Explored as Targeting Delivery System for Neurodegenerative Disorders (60 views)
Int J Mol Sc (ISSN: 1422-0067linking, 1422-0067electronic, 1661-6596), 2020 Nov 23; 21(22): N/D-N/D.
Impact Factor: 4.556
View Export to BibTeX Export to EndNote
Assante R, Salvatore E, Nappi C, Peluso S, De Simini G, Di Maio L, Palmieri GR, Ferrara IP, Roca A, De Michele G, Cuocolo A, Pappata S, De Rosa A
* Autonomic disorders and myocardial 123I-metaiodobenzylguanidine scintigraphy in Huntington's disease (38 views)
J Nucl Cardiol (ISSN: 1071-3581linking, 1532-6551electronic), 2020 Aug 16; N/D: N/D-N/D.
Impact Factor: 3.847
View Export to BibTeX Export to EndNote
Sarappa C, Salvatore E, Filla A, Cocozza S, Russo CV, Sacca F, Brunetti A, De Michele G, Quarantelli M
* Functional MRI signal fluctuations highlight altered resting brain activity in Huntington's disease (329 views)
Brain Imaging Behav (ISSN: 1931-7557), 2017 Oct; 11(5): 1459-1469.
Impact Factor: 3.719
View Export to BibTeX Export to EndNote
Oliveri V, Bellia F, Grasso GI, Pietropaolo A, Vecchio G
* Trehalose-8-hydroxyquinoline conjugates as antioxidant modulators of Aβ aggregation (943 views)
Rsc Adv (ISSN: 2046-2069), 2016; 6(53): 47229-47236.
Impact Factor: 3.108
View Export to BibTeX Export to EndNote
Salvatore E, Quarantelli M, Russo C, Giorgio SM, Cervo A, Cocozza S, Di Maio L, Brunetti A, Filla A, De Michele G
* Default-Mode Network Alterations In Huntington'S Disease (339 views)
Second Joint Limpe / Dismov Sin Meeting Rome, 2013 Nov; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Quarantelli M, Salvatore E, Giorgio SM, Filla A, Cervo A, Russo CV, Cocozza S, Massarelli M, Brunetti A, De Michele G
* Default-mode network changes in Huntington's disease: an integrated MRI study of functional connectivity and morphometry (763 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013 Aug 19; 8(8): e72159-e72159.
Impact Factor: 3.534
View Export to BibTeX Export to EndNote
Bellia F, Vecchio G, Cuzzocrea S, Calabrese V, Rizzarelli E
* Neuroprotective features of carnosine in oxidative driven diseases (491 views)
Molecular Aspects Of Medicine (ISSN: 1872-9452, 0098-2997), 2011 Sep; 32(4-6): 258-266.
Impact Factor: 9.97
View Export to BibTeX Export to EndNote
Esmaeilzadeh M, Kullingsjo J, Ullman H, Varrone A, Tedroff J
* Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with huntington disease (375 views)
Clin Neuropharmacol (ISSN: 0362-5664), 2011 May; 34(3): 95-100.
Impact Factor: 2.166
View Export to BibTeX Export to EndNote
Varrone A, Halldin C
Molecular imaging of the dopamine transporter (542 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2010 Sep 1; 51(9): 1331-1334.
Impact Factor: 7.022
View Export to BibTeX Export to EndNote
Salvatore E, Di Maio L, Filla A, Ferrara AM, Rinaldi C, Sacca F, Peluso S, Macchia PE, Pappata S, De Michele G
* Benign hereditary chorea: Clinical and neuroimaging features in an Italian family (356 views)
Mov Disord (ISSN: 0885-3185, 1531-8257, 0885-3185linking), 2010 Jul 30; 25(10): 1491-1496.
Impact Factor: 4.48
View Export to BibTeX Export to EndNote
Cervenka S, Varrone A, Fransen E, Halldin C, Farde L
* PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans (553 views)
Synapse (ISSN: 0887-4476), 2010 Jun; 64(6): 478-485.
Impact Factor: 2.925
View Export to BibTeX Export to EndNote
Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA
* Nitric oxide in cell survival: a janus molecule (1106 views)
Antioxid Redox Signal (ISSN: 1557-7716, 1523-0864, 1523-0864linking), 2009 Nov; 11(11): 2717-2739.
Impact Factor: 7.581
View Export to BibTeX Export to EndNote
Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L
* Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (738 views) (PDF 259 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Oct; 36(10): 1639-1650.
Impact Factor: 4.531
View Export to BibTeX Export to EndNote
Coppola G, Fortunato D, Auricchio G, Mainolfi C, Operto FF, Signoriello G, Pascotto A, Salvatore M
* Bone mineral density in children, adolescents, and young adults with epilepsy (419 views)
Epilepsia (ISSN: 1528-1167, 0013-9580), 2009 Sep; 50(9): 2140-2146.
Impact Factor: 4.052
View Export to BibTeX Export to EndNote
Palladino P, Ronga L, Benedetti E, Rossi F, Ragone R
* Peptide Fragment Approach to Prion Misfolding: The Alpha-2 Domain (402 views)
Int J Pept Res Ther (ISSN: 1573-3149, 0929-5666), 2009 Sep; 15(3): 165-176.
Impact Factor: 0.869
View Export to BibTeX Export to EndNote
Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM
* Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity (1004 views)
Nature Reviews Neuroscience (ISSN: 1471-0048), 2007 Oct; 8(10): 766-775.
Impact Factor: 24.52
View Export to BibTeX Export to EndNote
Fujita M, Varrone A, Kim KM, Watabe H, Zoghbi SS, Seneca N, Tipre D, Seibyl JP, Innis RB, Iida H
* Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [ 123I]epidepride SPET (354 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 May; 31(5): 644-654.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Delforge J, Bottlaender M, Pappata S, Loc'h C, Syrota A
* Absolute quantification by positron emission tomography of the endogenous ligand (343 views)
J Cereb Blood Flow Metab (ISSN: 0271-678x), 2001 May; 21(5): 613-630.
Impact Factor: 5.477
View Export to BibTeX Export to EndNote
* Curcumin-Loaded Nanoparticles Based on Amphiphilic Hyaluronan-Conjugate Explored as Targeting Delivery System for Neurodegenerative Disorders (60 views)
Int J Mol Sc (ISSN: 1422-0067linking, 1422-0067electronic, 1661-6596), 2020 Nov 23; 21(22): N/D-N/D.
Impact Factor: 4.556
View Export to BibTeX Export to EndNote
Assante R, Salvatore E, Nappi C, Peluso S, De Simini G, Di Maio L, Palmieri GR, Ferrara IP, Roca A, De Michele G, Cuocolo A, Pappata S, De Rosa A
* Autonomic disorders and myocardial 123I-metaiodobenzylguanidine scintigraphy in Huntington's disease (38 views)
J Nucl Cardiol (ISSN: 1071-3581linking, 1532-6551electronic), 2020 Aug 16; N/D: N/D-N/D.
Impact Factor: 3.847
View Export to BibTeX Export to EndNote
Sarappa C, Salvatore E, Filla A, Cocozza S, Russo CV, Sacca F, Brunetti A, De Michele G, Quarantelli M
* Functional MRI signal fluctuations highlight altered resting brain activity in Huntington's disease (329 views)
Brain Imaging Behav (ISSN: 1931-7557), 2017 Oct; 11(5): 1459-1469.
Impact Factor: 3.719
View Export to BibTeX Export to EndNote
Oliveri V, Bellia F, Grasso GI, Pietropaolo A, Vecchio G
* Trehalose-8-hydroxyquinoline conjugates as antioxidant modulators of Aβ aggregation (943 views)
Rsc Adv (ISSN: 2046-2069), 2016; 6(53): 47229-47236.
Impact Factor: 3.108
View Export to BibTeX Export to EndNote
Salvatore E, Quarantelli M, Russo C, Giorgio SM, Cervo A, Cocozza S, Di Maio L, Brunetti A, Filla A, De Michele G
* Default-Mode Network Alterations In Huntington'S Disease (339 views)
Second Joint Limpe / Dismov Sin Meeting Rome, 2013 Nov; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Quarantelli M, Salvatore E, Giorgio SM, Filla A, Cervo A, Russo CV, Cocozza S, Massarelli M, Brunetti A, De Michele G
* Default-mode network changes in Huntington's disease: an integrated MRI study of functional connectivity and morphometry (763 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2013 Aug 19; 8(8): e72159-e72159.
Impact Factor: 3.534
View Export to BibTeX Export to EndNote
Bellia F, Vecchio G, Cuzzocrea S, Calabrese V, Rizzarelli E
* Neuroprotective features of carnosine in oxidative driven diseases (491 views)
Molecular Aspects Of Medicine (ISSN: 1872-9452, 0098-2997), 2011 Sep; 32(4-6): 258-266.
Impact Factor: 9.97
View Export to BibTeX Export to EndNote
Esmaeilzadeh M, Kullingsjo J, Ullman H, Varrone A, Tedroff J
* Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with huntington disease (375 views)
Clin Neuropharmacol (ISSN: 0362-5664), 2011 May; 34(3): 95-100.
Impact Factor: 2.166
View Export to BibTeX Export to EndNote
Varrone A, Halldin C
Molecular imaging of the dopamine transporter (542 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2010 Sep 1; 51(9): 1331-1334.
Impact Factor: 7.022
View Export to BibTeX Export to EndNote
Salvatore E, Di Maio L, Filla A, Ferrara AM, Rinaldi C, Sacca F, Peluso S, Macchia PE, Pappata S, De Michele G
* Benign hereditary chorea: Clinical and neuroimaging features in an Italian family (356 views)
Mov Disord (ISSN: 0885-3185, 1531-8257, 0885-3185linking), 2010 Jul 30; 25(10): 1491-1496.
Impact Factor: 4.48
View Export to BibTeX Export to EndNote
Cervenka S, Varrone A, Fransen E, Halldin C, Farde L
* PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans (553 views)
Synapse (ISSN: 0887-4476), 2010 Jun; 64(6): 478-485.
Impact Factor: 2.925
View Export to BibTeX Export to EndNote
Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA
* Nitric oxide in cell survival: a janus molecule (1106 views)
Antioxid Redox Signal (ISSN: 1557-7716, 1523-0864, 1523-0864linking), 2009 Nov; 11(11): 2717-2739.
Impact Factor: 7.581
View Export to BibTeX Export to EndNote
Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L
* Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (738 views) (PDF 259 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Oct; 36(10): 1639-1650.
Impact Factor: 4.531
View Export to BibTeX Export to EndNote
Coppola G, Fortunato D, Auricchio G, Mainolfi C, Operto FF, Signoriello G, Pascotto A, Salvatore M
* Bone mineral density in children, adolescents, and young adults with epilepsy (419 views)
Epilepsia (ISSN: 1528-1167, 0013-9580), 2009 Sep; 50(9): 2140-2146.
Impact Factor: 4.052
View Export to BibTeX Export to EndNote
Palladino P, Ronga L, Benedetti E, Rossi F, Ragone R
* Peptide Fragment Approach to Prion Misfolding: The Alpha-2 Domain (402 views)
Int J Pept Res Ther (ISSN: 1573-3149, 0929-5666), 2009 Sep; 15(3): 165-176.
Impact Factor: 0.869
View Export to BibTeX Export to EndNote
Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM
* Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity (1004 views)
Nature Reviews Neuroscience (ISSN: 1471-0048), 2007 Oct; 8(10): 766-775.
Impact Factor: 24.52
View Export to BibTeX Export to EndNote
Fujita M, Varrone A, Kim KM, Watabe H, Zoghbi SS, Seneca N, Tipre D, Seibyl JP, Innis RB, Iida H
* Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [ 123I]epidepride SPET (354 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 May; 31(5): 644-654.
Impact Factor: 3.935
View Export to BibTeX Export to EndNote
Delforge J, Bottlaender M, Pappata S, Loc'h C, Syrota A
* Absolute quantification by positron emission tomography of the endogenous ligand (343 views)
J Cereb Blood Flow Metab (ISSN: 0271-678x), 2001 May; 21(5): 613-630.
Impact Factor: 5.477
View Export to BibTeX Export to EndNote
18 Records (16 excluding Abstracts).
Total impact factor: 96.292 (92.758 excluding Abstracts).
Total 5 year impact factor: 96.317 (92.302 excluding Abstracts).
Total impact factor: 96.292 (92.758 excluding Abstracts).
Total 5 year impact factor: 96.317 (92.302 excluding Abstracts).
477 views. Last view on Sunday 21 May 2023, 12:01:26
ibb.cnr.it
